Cover Image
市場調查報告書

處方止痛藥的分析與預測 2015-2020年:類鴉片物質止痛藥、抗痙攣止痛藥、注射/吸入止痛藥、局部/經皮止痛藥、醫療大麻 - 全球市場、競爭、機會

Prescription Pain Drugs - Including Opioid, Anticonvulsant, Injectable/Inhaled, Topical/Transdermal, Medical Marijuana-Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts

出版商 Amadee & Company, Inc. 商品編碼 338337
出版日期 內容資訊 英文 275 Pages
訂單完成後即時交付
價格
Back to Top
處方止痛藥的分析與預測 2015-2020年:類鴉片物質止痛藥、抗痙攣止痛藥、注射/吸入止痛藥、局部/經皮止痛藥、醫療大麻 - 全球市場、競爭、機會 Prescription Pain Drugs - Including Opioid, Anticonvulsant, Injectable/Inhaled, Topical/Transdermal, Medical Marijuana-Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts
出版日期: 2015年09月01日 內容資訊: 英文 275 Pages
簡介

本報告以處方止痛藥為主題,提供關於疼痛藥理學及止痛的詳細的討論,產品級、用途、製造商市場佔有率、市場促進要素、研發產品線分析,類鴉片物質止痛藥、抗痙攣止痛藥、注射/吸入止痛藥、局部/經皮止痛藥、醫療大麻市場全面的分析,及主要企業簡介,為您概述為以下內容。

摘要整理

簡介

  • 報告的目的
  • 調查手法和資訊來源
  • 統計相關註解

疼痛藥理學及止痛

  • 疼痛概要
  • 持續時間的疼痛
  • 急性疼痛
  • 慢性疼痛
  • 種類的疼痛
  • 傷害性疼痛
  • 發炎性疼痛
  • 神經性疼痛
  • 對疼痛的情動反應
  • 疼痛信號傳輸系統
  • 疼痛偵測
  • 疼痛信號傳達設備的功能特徵
  • 侵害接受器、其他

處方止痛藥市場

  • 疼痛的種類
  • 市場區隔:疼痛的重症度別
  • 市場:產品各級
  • 市場展望
  • 類鴉片物質市場:各用途
  • 癌症疼痛最大的區分
  • 市場佔有率
  • 推動市場的要素
  • 研發產品線

類鴉片物質止痛藥市場

  • 瞬間放出 vs. 持續放出市場
  • 持續放出型類鴉片物質市場:各品牌、級、製造廠商
  • 類鴉片物質處方藥
  • 對違法啟封防止/低依賴性類鴉片物質的關注
  • DEA許可、其他90天的處方

抗痙攣止痛藥市場

  • 神經性疼痛幾乎未受理解
  • 神經性疼痛治療藥市場
  • Gabapentin現在是學名藥市場
  • Lyrica減少的預測
  • Lyrica的銷售額
  • 銅鈸其他的銷售額、其他

注射/吸入止痛藥市場

  • Bridion利基產品
  • 歐洲Bridion銷售
  • Bridion的銷售額預測
  • Paion的M6G
  • Ofirmev 有大市場可能性的、其他

局部/經皮止痛藥市場

  • Lidoderm壟斷市場
  • 回收及學名藥給予Duragesic 損失
  • Flector貼片的銷售額
  • Ionsys 開發再開始
  • Voltaren的銷售額、其他

醫療大麻

  • Dronabinol, Nabilone, Nabiximols
  • 大麻
  • 法律上的情形
  • 健康問題
  • 大麻素受體、大麻素、其他

企業簡介

圖表

目錄

Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. At some point, everyone experiences pain. Pain may be described according to severity (mild, moderate, severe), duration (acute or chronic) or type (nociceptive, inflammatory, neuropathic).

Mild-to-moderate pain, such as orthopedic and soft tissue-related pain, generally is treated with NSAIDs, celecoxib (Pfizer's Celebrex), or mild opioid analgesics, such as tramadol. Moderate-to-moderately severe pain, such as post-operative pain, orthopedic pain, and chronic back pain, generally is treated with opioid analgesics, including short-acting opioids such as hydrocodone, oxycodone, oxymorphone, and morphine, as well as extended-release formulations of oxycodone, oxymorphone, and morphine. Severe pain, including post-operative and cancer pain, generally is treated with fentanyl products, such as Duragesic, Actiq, and Fentora, as well as morphine formulations, such as Avinza and Kadian.

This report deals with prescription drugs used to treat pain. While the Prescription Pain Drug market is relatively small and very mature, there are many new products coming online that have significant sales potential including Pfizer's Remoxy, Oxycodone NT and Embeda drugs, AcelRx's Zlaviso, Eagalet Corp's Oxayado, Endo/BDSI's Buprenorphine, GW Pharmaceuticals' Sativex, Insys' Subsys and dronabinol OS, Marinus' ganaxolone, as well as Bedrocan's and Tweed's medical marijuana offerings, among others.

Ultimately however, Prescription Pain Drugs are very important because without them life would be intolerable for millions of people.

For example, an estimated 50% of cancer patients experience some form of pain, which increases to 90% for patients with advanced-stage disease. Even worse, as many as 50% of patients may be under-treated for cancer-associated pain.

This report provides:

  • In-depth discussion of Pain Pharmacology and Analgesia.
  • Overview of the Prescription Pain Drugs market by product class, applications, producer market shares, market drivers and R&D pipelines.
  • Comprehensive analysis of the markets for Opioid, Neuropathic, Injectable/Inhaled, Topical/Transdermal and Medical Marijuana drugs used to treat pain.

Additionally, detailed profiles of 32 leading companies involved in the Prescription Pain Drugs industry are given. The report also includes 46 tables and 30 figures.

Table of Contents

EXECUTIVE SUMMARY

INTRODUCTION

  • Report Objectives
  • Methodology and Sources
  • Statistical Notes

PAIN PHARMACOLOGY AND ANALGESIA

  • Pain Overview
  • Pain According to Duration
  • Acute Pain
  • Chronic Pain
  • Pain According To Type
  • Nociceptive Pain
  • Inflammatory Pain
  • Neuropathic Pain
  • Emotional Response To Pain
  • Pain Signaling System
  • Pain Detection
  • Functional Characteristics Of Pain Signaling Apparatus
  • Nociceptors
  • Primary Sensory Neurons
  • Primary Sensory Neurons And The Spinal Cord
  • Spinal Cord Neurons
  • Projection Neurons And The Spinal Cord
  • Spinal Interneurons
  • Pain Characteristics
  • Animal Models Of Nociception/Pain
  • Neurochemical Characteristics Of The Nociceptive Signaling System
  • Transmission Of Nociceptive Information From The Periphery To The Spinal Cord
  • Nociceptive Neurotransmitters And Their Target Receptors
  • Excitatory Amino Acids And Their Receptors
  • Glutamate Receptors
  • NMDA Receptors
  • AMPA Receptors
  • Kainate Receptors
  • Metabotropic Glutamate Receptors (mGluRs)
  • Excitatory Amino Acid Transporters (EEATs)
  • Glycine Transporters (GlyTs)
  • Co-Containment Of Neurotransmitters In Nerve Terminals
  • Descending Modulation Of Nociception
  • Pharmacological Treatment Of Pain: Analgesics And Adjuvants
  • Major Aims Of the Treatment Of Clinical Pain
  • Pharmacological Management Of Pain
  • Current Treatment Guidelines
  • Controlled Or Sustained Release Oral Formulations
  • Analgesic Agents
  • Non-Opioid Analgesics
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Opioid Analgesics
  • Commonly Prescribed Opioid Analgesics
  • Strong Opioid Analgesics
  • Morphine
  • Oxycodone
  • Methadone
  • Hydromorphone
  • Fentanyl
  • Weak Opioid Analgesics
  • Codeine
  • Pethidine (Meperidine)
  • Tramadol
  • Partial Opioid Agonists/Antagonists: Buprenorphine
  • Opioid-Related Adverse Effects
  • Adjuvant Analgesics
  • Tricyclic Antidepressants
  • Anticonvulsants
  • Anti-Arrhythmics
  • Topical Agents
  • Lignocaine (Lidocaine)
  • Capsaicin
  • NMDA Receptor Antagonists
  • Ketamine
  • Dextromethorphan
  • Alpha(2)-Adrenergic Receptor Agonists
  • Invasive Procedures
  • Neurolytic Celiac Plexus Blockade
  • Implantable Intrathecal Drug Delivery
  • Spinal Cord Stimulation
  • Spinal Cord Stimulation
  • Future Trends

PRESCRIPTION PAIN DRUGS MARKET

  • Types Of Pain
  • Markets Segmented By Pain Severity
  • Market By Product Class
  • Market Outlook To 2020
  • Opioids Market By Application
  • Cancer Pain Is The Largest Segment
  • Market Shares
  • Market Drivers
  • R&D Pipeline

OPIOID PAIN DRUGS MARKET

  • Instant Vs. Extended Release Markets
  • Extended Release Opioids Market By Brand, Class And Producer
  • Opioid Prescriptions
  • Focus Now On Tamper Resistant/Less Addictive Opioids
  • DEA Allows 90-Day Rx's
  • DEA Reschedules Hydrocodone Combination Products
  • OxyContin Tamper Resistant Extends Franchise
  • Advances In Opioid Receptor Research
  • Testosterone Issues And Chronic Opioid Use
  • FDA Tamper Resistance Guidance
  • Opioids From Yeast

ANTICONVULSANT PAIN DRUGS MARKET

  • Neuropathic Pain Is Poorly Understood
  • Neuropathic Pain Drug Market
  • Gabapentin Now A Generic Market
  • Lyrica Forecast To Fall
  • Lyrica Sales
  • Cymbalta Sales
  • Generic Cymbalta Producers
  • Targeted Secretion Inhibitors For Peripheral Neuropathic Pain
  • Allergan's AGN-214868 Market Potential
  • Nerve Growth Inhibitors Put On Hold

INJECTABLE/INHALED PAIN DRUGS MARKET

  • Prialt Is A Niche Product
  • Bridion Launched In Europe
  • Bridion Sales To 2020
  • Paion's M6G
  • Post-Operative Pain Market Underserved
  • Ofirmev Has Significant Market Potential
  • Ofirmev Peak Revenues
  • Ofirmev Satisfies A Key Need
  • Surgery Pain Is Poorly Addressed
  • Opiates Complications Are Frequent And Costly
  • Intravenous IV NSAIDs Have Limitations
  • Ofirmev Reduces Pain And Fever
  • EU Experience Backs Ofirmev's Potential In The U.S.
  • Ofirmev U.S. Sales Outlook
  • Ofirmev Patented Through 2021
  • License With Terumo
  • Tanezumab Moving Forward
  • Tanezumab Sales Outlook

TOPICAL/TRANSDERMAL PAIN DRUGS MARKET

  • Lidoderm Dominates The Market
  • Recall And Generics Hurt Duragesic
  • Flector Patch Has Plateaued
  • Flector Patch Sales
  • Ionsys Back In Development
  • Voltaren Continues To Perform Well
  • Voltaren Gel Sales
  • Zingo
  • NeurogesX's Qutenza
  • AmiKet Cream
  • Durect's Sufentanil Patch

MEDICAL MARIJUANA

  • Dronabinol, Nabilone, Nabiximols
  • Marijuana
  • Legal Situation
  • Health issues
  • Cannabinoid Receptors And Cannabinoids
  • THC
  • CBD
  • Potency Trends
  • Research Obtained Through National Institute Of Drug Abuse
  • Delta-9-tetrahydrocannabinol
  • Cannabidiol
  • Pharmaceutical Forms of Cannabinoids
  • Marijuana And Cannabinoids Potential In Cancer Pain
  • Marijuana Pharmaceuticals For Pain
  • Nabiximols
  • Dronabinol
  • Nabilone
  • Potential Harms Of Marijuana
  • Cancer
  • Lung Problems
  • Neuropsychiatric
  • Other Problems
  • Outlook
  • Global Cannabis Market
  • Most Widely Cultivated Drug Plant
  • Global Cannabis Production
  • Marijuana Market vs. OTC Analgesic Market
  • Marinol
  • Medical Marijuana Market: Cannabis Vs. Dronabinol
  • Number Of Medical Marijuana Patients

COMPANY PROFILES

  • AcelRx Pharmaceuticals Inc. (Company Overview, Zalviso, NanoTab Formulation, Targets U.S. PCA Market, Zalviso U.S. Sales To 2019, ARX-02 Targets Cancer Breakthrough Pain, ARX-03 Targets Office-Based Surgery Market)
  • Acura Pharmaceuticals, Inc.(Company Overview, Key Target-Based Actions, Key Technologies, Aversion Technology, Oxaydo™, U.S. Market Opportunity, Aversion Technology Opioid Products in Development, Physicians Highly Concerned With Diversion, Opioid Products And Health Insurers Costs, Licensing Agreements, Regulatory Risks, Clinical Risks, Commercial Risks, Intellectual Property Risks, Financial Risks)
  • Allergan plc (Company Overview, Actavis, Cebranopadol, Actavis Elizabeth LLC)
  • Antibe Therapeutics Inc (Company Overview, ATB-346, Hydrogen Sulfide May Help Mucosal Defense, ATB-346 Development Process, ATB-346 Advantages, Promising Signs Of GI Protection, Future Trials Funded With Partnership, Intellectual Property, ATB-346 Suspended Development, Results Of Additional Testing)
  • Bedrocan Cannabis Corp. (Company Overview, Strategy, Medical Marijuana, Competitive Advantages, Bedrocan BV, Pharmaceutical Quality Product, Advantages To Bedrocan BV Partnership, License Agreement Lowers Risk, License Agreement Provides Upside, South American Countries Looking To Legalize, Bedrocan Product Suite, Bedrocan, Bedropuur, Bedica, Bediol, Bedrolite, Bedrobinol, Small Product Offerings, CFPC Preliminary Guidelines, Facilities, Domestic Production Facility, State of the Art Growing Operations, Production Flow, Annual Sales Volume, Cost Per Gram, Marketing Strategy, Retail Prices, Patient Sign up Process, Current Patient Composition, Patient Count Growing, Patient Consumption Rates, Physician Outreach and Medical Advisory Board, ISO-9000 Certified, Standardization Advantages, Management And Directors Relationships, Experience, Enterprise Value, Financials)
  • BioDelivery Sciences International, Inc (Company Overview, Onsolis Fills A Niche Opportunity, BUNAVAIL, BELBUCA™, Clonidine Topical Gel)
  • Cara Therapeutics, Inc. (Company Overview, CR845, Kappa Vs. Mu Opioid Receptors, No Interaction With The Central Nervous System, Limited Abuse Potential, Safer Drug-Drug Interaction Profile, IV To Oral Stepdown, Intravenous CR845 And Acute Pain, Phase 3 Clinical Development Plans, CR701, Intellectual Property, Financial)
  • Collegium Pharmaceutical, Inc. (Company Overview, DETERx Platform Technology, Xtampza)
  • Covidien plc (Company Overview, Exalgo)
  • Durect Corporation (Company Overview, POSIDUR)
  • Egalet Corp (Company Overview, OXAYDO™ and SPRIX® Licensing Rights, OXAYDO™, Financial)
  • Elite Pharmaceuticals, Inc. (Company Overview, Products, Controlled Release Dosage, Patents, Pipeline)
  • Endo International plc (Company Overview, Opana, Partners With BDSI On Buprenorphine)
  • Grünenthal GmbH (Company Overview, Zalviso®, Neosaxitoxin, INTAC®)
  • GW Pharmaceuticals plc (Company Overview, Sativex®, Sativex® Phase 3 Trials, Sativex® Multiple Sclerosis Market, Sativex® Cancer Pain Market, Financials)
  • Indivior plc (Company Overview, Global Leader In Addiction Treatment, Buprenorphine, Suboxone And Naloxone, Regulation, 60% Market Share, Buprenorphine Prescriptions And Payors, Future Growth And Pipeline Opportunities, International Expansion, Sales By Product To 2024)
  • Insys Therapeutics Inc (Company Overview, Business Model, Top Branded Drug In The Breakthrough Cancer Pain Segment, Fentanyl, Best In Class Characteristics, 18 Months To Become Leading Branded BTCP Product, Can Successfully Expand Subsys' Label, Two Key Technology Platforms, Expertise In Producing Synthetic Cannabinoids, Dronabinol Oral Solution, Dronabinol OS Has Improved Attributes, Dronabinol OS Peak Sales, Numerous Sublingual Spray Pipeline Opportunities, Buprenorphine Sublingual Spray, Ondansetron Sublingual Spray, Intellectual Property And Other Barriers To Entry, Financial)
  • Intellipharmaceutics International Inc. (Company Overview, Key Indications, Key Target-based Actions, Key Technologies, Rexista™, Pregabalin CR)
  • Johnson & Johnson (Company Overview, Growth Of Ultram ER Remains Sluggish, Nucynta Has Good Potential)
  • King Pharmaceuticals (Pfizer)(Company Overview)
  • Lannett Company, Inc. (Company Overview, Oxycodone)
  • Marinus Pharmaceuticals Inc (Company Overview, Ganaxolone/ Allopregnanolone, Intellectual Property, Epilepsy Drugs Market)
  • Mayne Pharma Group Ltd (Company Overview, Products, Pain Management Drugs, Oxycodone, Kapanol™ and Kadian™)
  • Nektar Therapeutics (Company Overview, NKTR-181, Nektar Novel Opioids)
  • NicOx SA (Company Overview, CINODs)
  • Pacira Pharmaceuticals Inc (Company Overview, EXPAREL)
  • Pfizer Inc. (Company Overview, EMBEDA®, Key Likeability Studies, Settlement With Purdue And Patent Overhang, Oxycodone NT Phase III Trials, Avinza)
  • Purdue Pharma, L.P. (Company Overview, Oxycontin)
  • Raptor Pharmaceutical Corp., (Company Overview, Tezampanel/NGX426)
  • Teva Pharmaceutical Industries Limited (Company Overview, Fentora Continues To Struggle, U.S. Growth Opportunity Is Limited)
  • Trevena Inc. (Company Overview, TRV130, TRV734)
  • Tweed Marijuana Inc. (Company Overview, Medical Marijuana, Goal Is Perpetual Harvest, Smiths Falls Facility, Security, Growing Equipment, Laboratory, Expansion Plans, Smith Falls Grow Operations, Smiths Falls Capacity To Double, Mother Room Houses ~5,000 Plants, Up To 10,000 kg/Year, Tweed Farms, Tweed Farms Property, Tweed Farms Grow Operations, 70% Lower Costs, Capacity Up To 3,700 kg, Factors Offsetting Benefits Of Greenhouse Production, Product Offerings, Cannabis Oils, Pricing, Vaporizers, Radiation, Other Potential Revenue Streams, Direct-to-Consumer Sales Process, Go-To-Market Strategy, Patient Acquisition, Medical Advisory Board, Canadian AIDS Society, Bedrocan Acquisition, Quebec Registry For Medical Marijuana, Financials)
  • Zogenix, Inc (Company Overview, First Hydrocodone ER With No APAP, Zohydro® Is Met With Controversy)

TABLES

  • 1.) Pain Management By Class Of Drug Used
  • 2.) Pain Drugs Ranked By Relative Potency To Morphene
  • 3.) Global Prescription Pain Drugs Market By Product Class ($ Billion): 2015-2020
  • 4.) Opioid Drugs Market By Application ($ Billion): 2015
  • 5.) Prescription Pain Drug Producers Sales ($ Million) and Market Shares (%): 2015
  • 6.) Pain Management Drug Pipeline by Stage (PC, I, II, III, NDA, Market): 2015
  • 7.) Opioids Drugs Production: Instant Vs. Extended Release ($ Million): 2015-2019
  • 8.) Opioids Extended Release Drugs Production By Brand, Class And Producer ($ Million): 2015-2019
  • 9.) Extended Release Opioid Drugs Market By Company And Product, Including Sales ($ Million), Prescriptions (Million), Market Share (%), Growth Rate (%): 2012-2019
  • 10.) Instant Release Opioid Drugs Prescriptions (Million) By Class: 2015
  • 11.) Tamper-Resistant Opioid Products In Development: 2015
  • 12.) Comparison of Select Branded Extended Release Opioids
  • 13.) Anticonvulsant Drugs For Pain Production By Product (Gabapentin, Lyrica, Cymbalta) ($ Billion): 2015-2020
  • 14.) U.S. Topical NSAID Market by Product: 2012-2019
  • 15.) Clinical Studies And The Effect of Smoked Marijuana On Pain
  • 16.) Worldwide Number (Millions) and Prevalence (%) of Users by Type of Illicit Drug: 2012
  • 17.) Global Cannabis Production Volume (MT), Value (USD) and Average Selling Price (Million USD/MT): 2015-2020
  • 18.) Global Sales of Over-the-Counter (OTC) Pharmaceuticals by Application (USD Million): 2013
  • 19.) Medical Marijuana Production: Cannabis Vs. Dronabinol (USD Million): 2015-2020
  • 20.) Medical Marijuana Patients (Million), Patient Consumption (Grams/Month), Grams Consumed (Million), Production Price ($/Gram), Production Value ($ Million): U.S., Canada, ROW: 2015
  • 21.) U.S. Medical Marijuana Patients By State (Number), State Population (Number), Number Of Patients Per 1,000 State Residents: 4Q2014
  • 22.) Canada Marihuana For Medical Purposes Regulations Patients And Growth Rate (Number, %): 2014-2034
  • 23.) AcelRx's ARX-02 Vs. Onsolis And Abstral: Onset of Action/PK Profile Comparison
  • 24.) Acura Pharmaceuticals Aversion Opioid Products In Development: 2015
  • 25.) Acura Pharmaceuticals Oxaydo (AVERSION Oxycodone) Royalty Revenues: 2015-2024
  • 26.) Bedrocan Operations Timeline: 2012-2015
  • 27.) Bedrocan Cannabis Corp. Import Facility Features
  • 28.) Bedrocan Cannabis Corp. Domestic Facility Features
  • 29.) Bedrocan Cannabis Registration Application Form
  • 30.) Bedrocan Cannabis Corp. Income Statement: 2015-2019
  • 31.) Oxaydo Prescriptions (Thousands), Revenues ($ Thousands), Market Shares (%) By Product Strength: 2015-2025
  • 32.) Sativex® Multiple Sclerosis Revenue Model: 2013-2027
  • 33.) Sativex® Cancer Pain Revenue Model: 2013-2027
  • 34.) GW Pharmaceuticals Income Statement (GBP Million): 2011-2017
  • 35.) Indivior U.S. Pipeline: Stages Of Development And Earliest Approval Dates: 2014-2020
  • 36.) Indivior Non-U.S. Pipeline: Stages Of Development And Earliest Approval Dates: 2014-2020
  • 37.) Indivior Revenue Build For Suboxone And New Drug Pipeline ($ Million): 2014-2024
  • 38.) Breakthrough Cancer Pain Products Competitive Landscape
  • 39.) U.S. Market For Epilepsy Drugs By Product ($ Million): 2014-2025
  • 40.) Mayne Pharma Drug Portfolio: Key Current Molecules ($ Million): 2015
  • 41.) Key Molecules Of Mayne Pharma's US Generic Portfolio ($ Million): 2015
  • 42.) Smiths Falls Estimated Production Breakdown
  • 43.) Tweed Farms Estimated Production Breakdown
  • 44.) Indoor vs. Greenhouse Growing Methodology Comparison
  • 45.) Tweed Products and Prices
  • 46.) Tweed Marijuana Inc. Income Statement: 2014-2016

FIGURES

  • 1.) Nocicpetive Pain Pathways
  • 2.) Glutamate Receptors
  • 3.) WHO Three-Step Analgesic Ladder
  • 4.) Lifetime Non-Medical Use of Selected Pain Relievers, Age 12 or Older: 2013
  • 5.) Positioning of Antibe's Lead Asset ATB-346 In The Market
  • 6.) Antibe's ATB-346 Development Process
  • 7.) Bedrocan
  • 8.) Bedropuur
  • 9.) Bedica
  • 10.) Bediol
  • 11.) Bedrolite
  • 12.) Canadian LP Pricing and Strain Offerings by Company (C$/Gram, Number Strains)
  • 13.) Enterprise Value Spectrum for Public Canadian Marijuana LPs (C$): 2015
  • 14.) Neural Synapse With Opioid Receptors
  • 15.) Cara Therapeutics Clinical Development Trial Timelines: 2013-2018
  • 16.) Cara Therapeutics Product Candidates And Commercialization Rights
  • 17.) Subsys - Single-use Sublingual Fentanyl Spray
  • 18.) Insys Cannabinoid Manufacturing Capabilities
  • 19.) Insys' Dronabinol Franchise Summary
  • 20.) Insys' Dronabinol Oral Solution Commercial Opportunity
  • 21.) Insys' Sublingual Spray Pipeline: 2014-2016
  • 22.) Insys' Buprenorphine / Naloxone Sublingual Spray Opportunity
  • 23.) Mechanism for Ganaxolone and Allopregnanolone
  • 24.) Aerial View of Tweed's Smiths Falls Facility
  • 25.) Smiths Falls Production Facility
  • 26.) Evolution of Smiths Falls' Installed Capacity: 2014-2016
  • 27.) Smiths Falls' Mother Room and Cuttings
  • 28.) Tweed Farms Production Facility
  • 29.) Marijuana Vaporizers
  • 30.) Strains Produced At Smiths Falls
Back to Top